Bladder cancer updates from the second half of 2026

Share :
Published: 18 Nov 2026
Views: 20
Rating:
Save
Prof Alison Birtle, Dr Ignacio Duran, Prof Axel Merseburger, Dr José Domínguez-Escrig and Prof Morgan Rouprêt

Prof Alison Birtle (Rosemere Cancer Centre, Lancashire Teaching Hospitals, Preston, UK), Dr Ignacio Duran (Hospital Universitario Marqués de Valdecilla, Santander, Spain), Prof Axel Merseburger (Universitätsklinikum Schleswig-Holstein, Lübeck, Germany), Dr José Domínguez-Escrig (Fundación Instituto Valenciano de Oncología, Valencia, Spain) and Prof Morgan Rouprêt (Pitié-Salpétrière Hospital, Paris, France) discuss bladder cancer updates from the second half of 2026.

The panel reviews emerging evidence on perioperative treatment for muscle-invasive bladder cancer (MIBC), considering whether chemo-immunotherapy remains the preferred approach and how recent clinical trial findings could change treatment strategies. The experts also explore new approaches for advanced bladder cancer, discussing whether further treatment intensification can improve outcomes or whether new therapeutic options are needed.

The discussion also examines the growing role of biomarkers and individual patient factors in personalising bladder cancer management, including how these may help guide treatment selection and identify patients most likely to benefit from specific approaches.

Thinking outside the box
Reinventing perioperative treatment in MIBC in 2026: Is chemo-immunotherapy over in this clinical context?
New approaches in the advanced disease setting: Is more better, or are new drugs needed?
Personalising treatment: The value of biomarkers and patient factors in managing patients with bladder cancer
Take home messages

 

Supported by an independent educational grant from Johnson & Johnson